<p>Miracle Mile Advisors LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在礼来公司的持股增加了 7.9%。该公司在本季度额外购买了 1,447 股后，持有该公司 19,766 股股票。到最近一个季度末，Miracle Mile Advisors LLC 在礼来公司的持股价值为 15,081,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
<p>其他机构投资者和对冲基金最近也调整了对该公司的持股。住友三井金融集团在第二季度购买了价值约 27,000 美元的礼来公司新股份。Evolution Wealth Management Inc. 在第二季度获得了价值 29,000 美元的礼来公司新股份。Steph &amp; Co. 在第三季度将其在礼来公司的持股增加了 290.0%。Steph &amp; Co. 现在拥有 39 股该公司股票，价值 30,000 美元，此前在上个季度又购买了 29 股。Financial Gravity Companies Inc. 在第二季度购买了价值 31,000 美元的礼来公司新股份。最后，Bare Financial Services Inc 在第二季度将其在礼来公司的持股增加了 263.6%。Bare Financial Services Inc 现在拥有 40 股该公司股票，价值 31,000 美元，此前在此期间又购买了 29 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
<h2>礼来公司的价格表现</h2>
<p>礼来公司股票在周五开盘价为 1,075.00 美元。该公司的市值为 1.02 万亿美元，市盈率为 52.59，市盈率增长比率为 1.09，贝塔值为 0.37。该公司的债务与股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,111.99 美元。该股票的 50 天简单移动平均线为 1,008.08 美元，200 天简单移动平均线为 848.52 美元。</p>
<ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。与去年同期相比，礼来公司的季度收入增长了 53.9%。礼来公司已将其 2025 财年的指导目标设定为每股收益 23.000-23.700 美元。平均而言，股票分析师预测礼来公司本财年的每股收益为 23.48 美元。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了季度股息，将于 3 月 10 日支付。记录在案的投资者将在 2 月 13 日获得每股 1.73 美元的股息。这相当于年化 6.92 美元的股息，收益率为 0.6%。该股息的除息日期为 2 月 13 日。这是礼来公司之前每季度 1.50 美元股息的积极变化。礼来公司的股息支付比率（DPR）为 33.86%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>礼来的新药数据为 2026 年设定了高风险赌注</li>
</ul>
<p>LLY 已成为几份研究报告的主题。Weiss Ratings 在 12 月 22 日的研究报告中重申了对礼来公司股票的 &#34;买入（b-）&#34; 评级。大和美国在 12 月 16 日的报告中将礼来公司从 &#34;持有&#34; 评级上调至 &#34;强力买入&#34; 评级。Cantor Fitzgerald 在 12 月 1 日的研究报告中重申了对礼来公司股票的 &#34;增持&#34; 评级。加拿大丰业银行在 11 月 13 日的研究报告中开始覆盖礼来公司的股票。他们设定了 &#34;行业表现优于大盘&#34; 的评级和 1,165.00 美元的目标价。最后，摩根大通将礼来公司的股票目标价从 1,050.00 美元上调至 1,150.00 美元，并在 11 月 18 日的报告中给予该公司 &#34;增持&#34; 评级。四位投资分析师对该股票给予了强力买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 1,155.36 美元。</p>
<p><strong>查看我们对 LLY 的最新分析</strong></p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来公司在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A. 领导。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过礼来公司</li>
<li>黄金警报</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>请勿删除，立即阅读</li>
<li>雷·达里奥说买入黄金。我说每月从中获利</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Miracle Mile Advisors LLC 在第三季度将其在礼来公司（NYSE: LLY）的持股增加了 7.9%，目前持有 19,766 股，价值 1508 万美元。其他机构投资者也调整了他们的持仓。礼来的股票开盘价为 1,075.00 美元，市值为 1.02 万亿美元，市盈率为 52.59。该公司报告第三季度每股收益为 7.02 美元，超出预期，并宣布季度股息为每股 1.73 美元，较之前的 1.50 美元有所上升。分析师对该股票维持积极评级，目标价格范围在 1,050 美元至 1,165 美元之间</p>

<p>Miracle Mile Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,766 shares of the company's stock after buying an additional 1,447 shares during the quarter. Miracle Mile Advisors LLC's holdings in Eli Lilly and Company were worth $15,081,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Miracle Mile Advisors LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在礼来公司的持股增加了 7.9%。该公司在本季度额外购买了 1,447 股后，持有该公司 19,766 股股票。到最近一个季度末，Miracle Mile Advisors LLC 在礼来公司的持股价值为 15,081,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
</div><p>Other institutional investors and hedge funds also recently modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph &amp; Co. boosted its holdings in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock valued at $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc grew its stake in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock valued at $31,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也调整了对该公司的持股。住友三井金融集团在第二季度购买了价值约 27,000 美元的礼来公司新股份。Evolution Wealth Management Inc. 在第二季度获得了价值 29,000 美元的礼来公司新股份。Steph &amp; Co. 在第三季度将其在礼来公司的持股增加了 290.0%。Steph &amp; Co. 现在拥有 39 股该公司股票，价值 30,000 美元，此前在上个季度又购买了 29 股。Financial Gravity Companies Inc. 在第二季度购买了价值 31,000 美元的礼来公司新股份。最后，Bare Financial Services Inc 在第二季度将其在礼来公司的持股增加了 263.6%。Bare Financial Services Inc 现在拥有 40 股该公司股票，价值 31,000 美元，此前在此期间又购买了 29 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>礼来公司的价格表现</h2>
</div><p>LLY stock opened at $1,075.00 on Friday. The firm has a market cap of $1.02 trillion, a P/E ratio of 52.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The stock has a 50-day simple moving average of $1,008.08 and a 200-day simple moving average of $848.52.</p>
<div class="lb-trans"><p>礼来公司股票在周五开盘价为 1,075.00 美元。该公司的市值为 1.02 万亿美元，市盈率为 52.59，市盈率增长比率为 1.09，贝塔值为 0.37。该公司的债务与股本比率为 1.71，速动比率为 1.24，流动比率为 1.55。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,111.99 美元。该股票的 50 天简单移动平均线为 1,008.08 美元，200 天简单移动平均线为 848.52 美元。</p>
</div><ul>
<li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 EPS. Eli Lilly and Company's quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。与去年同期相比，礼来公司的季度收入增长了 53.9%。礼来公司已将其 2025 财年的指导目标设定为每股收益 23.000-23.700 美元。平均而言，股票分析师预测礼来公司本财年的每股收益为 23.48 美元。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio (DPR) is 33.86%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，将于 3 月 10 日支付。记录在案的投资者将在 2 月 13 日获得每股 1.73 美元的股息。这相当于年化 6.92 美元的股息，收益率为 0.6%。该股息的除息日期为 2 月 13 日。这是礼来公司之前每季度 1.50 美元股息的积极变化。礼来公司的股息支付比率（DPR）为 33.86%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来的新药数据为 2026 年设定了高风险赌注</li>
</ul>
</div><p>LLY has been the topic of several research reports. Weiss Ratings reaffirmed a &#34;buy (b-)&#34; rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Daiwa America upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Tuesday, December 16th. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Scotiabank began coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $1,165.00 target price for the company. Finally, JPMorgan Chase &amp; Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $1,155.36.</p>
<div class="lb-trans"><p>LLY 已成为几份研究报告的主题。Weiss Ratings 在 12 月 22 日的研究报告中重申了对礼来公司股票的 &#34;买入（b-）&#34; 评级。大和美国在 12 月 16 日的报告中将礼来公司从 &#34;持有&#34; 评级上调至 &#34;强力买入&#34; 评级。Cantor Fitzgerald 在 12 月 1 日的研究报告中重申了对礼来公司股票的 &#34;增持&#34; 评级。加拿大丰业银行在 11 月 13 日的研究报告中开始覆盖礼来公司的股票。他们设定了 &#34;行业表现优于大盘&#34; 的评级和 1,165.00 美元的目标价。最后，摩根大通将礼来公司的股票目标价从 1,050.00 美元上调至 1,150.00 美元，并在 11 月 18 日的报告中给予该公司 &#34;增持&#34; 评级。四位投资分析师对该股票给予了强力买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 1,155.36 美元。</p>
</div><p><strong>View Our Latest Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我们对 LLY 的最新分析</strong></p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来公司在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A. 领导。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>GOLD ALERT</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>Do not delete, read immediately</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过礼来公司</li>
<li>黄金警报</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>请勿删除，立即阅读</li>
<li>雷·达里奥说买入黄金。我说每月从中获利</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Miracle Mile Advisors LLC 增持了礼来公司（Eli Lilly）的股票头寸 $LLY